SUBSCRIBERS
Cancer diagnostics firm Biolidics lodges prospectus for Catalist IPO
Published Mon, Nov 26, 2018 · 09:50 PM
Singapore
MEDICAL technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge Biomedics, lodged a preliminary prospectus on Friday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.
Details of the pricing, amount to be raised, and timing of the offering have not yet been announced. UOB is the sponsor, issue manager and placement agent for the IPO.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Cordlife directors offer differing views on future oversight if board is rejigged
Tesla lays off more staff in software, service teams, Electrek reports
Robinhood Crypto gets Wells notice from US SEC
Morgan Stanley strategists see inflation as key for path of US stocks
US: Wall Street opens higher as rate-cut hopes linger
Tyson raises outlook as lower costs boost chicken segment